CBD IV information · An informed conversation

CBD IV Therapy: Questions for Sante Patients

If you are looking into CBD IV therapy, start with clear information about the actual product and its status. Sante has published materials about Pico IV cannabidiol infusions. Contact the Hampton team to confirm current availability and discuss the evidence, regulatory information, and clinical questions before making treatment plans.

CBD IV Therapy
Start here

Confirm current availability directly with the clinic

Product details

Request the exact preparation and its regulatory status

Personal review

Bring your medications, health history, and specific questions

Contact the team

603-929-0084 · Hampton, New Hampshire

Get current information before planning care

CBD is cannabidiol, a compound found in cannabis. CBD IV therapy describes an intravenous preparation containing it. The product, ingredients, route, and intended use all matter when evaluating a proposal.

Published descriptions of a service do not establish its current availability. Ask the office which services are presently offered and what documentation applies to any proposed CBD preparation. This page is a starting point for questions, not confirmation that an infusion can be booked.

Review the FDA information about Pico IV

The FDA's published warning letter to Pico IV Inc., identified as CMS 700591, describes the company's intravenous CBD product as an unapproved new drug. It also raises concerns about injectable products and explains that an intravenously administered product does not meet the definition of a dietary supplement.

That letter concerns Pico IV and the product and marketing reviewed by FDA. It does not establish Sante's current inventory or services. Because Sante's earlier materials name Pico IV, this is relevant information to discuss before considering any proposed treatment. Ask for current, product-specific documentation rather than relying on an older promotional description.

Connect any benefit claim to the evidence

FDA approval of a prescription CBD medicine for certain seizure disorders does not establish approval of an IV CBD product. A claim about absorption, particle size, purity, or third-party testing also does not by itself demonstrate a clinical benefit.

Ask whether a proposed benefit has been studied in people using the same product and route for the same purpose. You should be able to discuss what is known, what is uncertain, and whether another approach would better address your concern.

Bring your health history into the discussion

FDA identifies liver injury, medication interactions, and changes in alertness among CBD concerns. These general safety findings do not establish a safe IV formulation or dose. Review the actual proposal with an appropriately qualified clinician and the professionals managing your existing treatment.

Bring a complete list of prescriptions, over-the-counter medicines, supplements, and other cannabinoid products. Share allergies, prior reactions, and relevant medical conditions. Do not replace prescribed care or reduce a medication because a product is described as natural.

  • What exact product and route are being proposed, and for what purpose?
  • What current regulatory documentation applies to that product?
  • Who would assess suitability and be responsible for care?
  • What are the evidence, risks, alternatives, and follow-up arrangements?

Request information from the Hampton team

Call 603-929-0084 to clarify the current service menu and bring your questions to the team. The clinic is at 861 Lafayette Road, Suite 3, in Hampton.

If you are learning about the practice, a free 15-minute introductory call can help you understand the next step. It does not provide clearance for an infusion or confirm that a particular product is available or appropriate.

Before your visit

Your questions, answered

Is CBD IV therapy currently available at Sante?

Contact the office to confirm the current service menu and the exact product under discussion. Sante has published Pico IV materials, but those descriptions should not be treated as confirmation of present availability or suitability.

Is an IV CBD product FDA-approved because a prescription CBD drug exists?

No. Approval applies to a particular drug product and its approved uses. Approval of a prescription CBD medicine for certain seizure disorders does not establish approval of an IV preparation or another use.

Why does this page mention an FDA letter to Pico IV?

Sante's published materials name Pico IV. FDA's letter to that company addresses its intravenous CBD product, so it is relevant to a product-specific discussion. The letter does not by itself describe Sante's current operations or establish the availability of a service.

Can CBD interact with my medicines?

Yes. FDA identifies potential medication interactions and other CBD risks. Bring a complete medication and supplement list and review the actual proposed product with an appropriately qualified clinician or pharmacist before making a decision.

Can I use the free call to book a CBD infusion?

Use the call to request current information and understand the next step. An introductory conversation is separate from clinical evaluation, and it does not establish that a particular infusion is available, appropriate, or cleared to proceed.

Related care and useful next steps

A conversation comes first

Care shaped around you.

Tell our team what has been affecting you and what you want to work toward. Start with a free 15-minute introductory consultation at The Sante Center in Hampton, New Hampshire.

861 Lafayette Road, Suite 3 · Hampton, NH 03842. Continue care with your primary care provider and other treating clinicians.

Request a conversation

Contact Us
First
Last
What would you like help with? *
Other services of interest (optional)

Sources and further reading

Clinic service information and independent resources used to explain the topic. These sources do not establish that a particular treatment is right for you.

  1. The Sante Center: previously published CBD IV article naming Pico IV
  2. FDA: published warning letter to Pico IV Inc., CMS 700591
  3. FDA: cannabis-derived products, CBD, and product-specific approval
  4. FDA: CBD safety concerns and unanswered questions

Meet the Sante team · Fees and appointment information

The Sante Center clinic

Our team brings together natural and integrative approaches to help you understand your health and explore care that is personal to you.

Book Your Free Consultation